A Clinical Evaluation of the MicroSTent® PeripherAl Vascular SteNt in Subjects With Arterial Disease Below the Knee (STAND)

  • End date
    Mar 1, 2024
  • participants needed
  • sponsor
    Micro Medical Solution, Inc.
Updated on 21 April 2022
vascular disease
limb ischemia
critical limb ischaemia


Randomized multicenter clinical trial consisting of two arms; one arm treated with PTA plus the MicroStent® System and one arm treated with PTA alone. Purpose to evaluate the safety and effectiveness of using the MicroStent® Peripheral Vascular Stent System, hereafter referred to as the MicroStent® System, for the treatment of infrapopliteal lesions in subjects with peripheral arterial disease.

Condition Peripheral Arterial Disease
Treatment standard PTA, MicroStent and Standard PTA
Clinical Study IdentifierNCT03477604
SponsorMicro Medical Solution, Inc.
Last Modified on21 April 2022


Yes No Not Sure

Inclusion Criteria

Subject is a male or a non-pregnant female adult between the age of 21 and 90 years old
Subject has documented clinical evidence of critical limb ischemia (CLI) in the target limb prior to the index procedure, with a Rutherford Classification score of 4-5
The subject, or subject's designated legal representative, has been informed of the nature of the study and is willing to provide written informed consent
Subject is willing to comply with all required follow-up visits
Subject life expectancy is ≥1 year per the Principal Investigator
Angiographic Inclusion Criteria
Target vessel reconstitutes at or above the ankle with inline flow to at least one patent (<50% stenosis) inframalleolar outflow vessel
Subject has a lesion, with ≥ 70% stenosis and ≤ 12.0 cm in length located at or distal to the tibial-peroneal trunk and above the tibiotalar joint; including the anterior tibial, posterior tibial or peroneal arteries
Target lesion has a reference vessel diameter of 2.5 - 4.5 mm
The target lesion is able to be crossed with a guidewire to facilitate treatment with the randomized device

Exclusion Criteria

Subject has a wound/ulcer on the forefoot with a surface area >4cm² or osteomyelitis involving the calcaneus bone
Subject had a prior or has a planned index limb amputation above the ankle
Subject is pregnant, plans to become pregnant, or is nursing
Subject has clinical conditions that severely inhibit X-ray or duplex ultrasound visualization (e.g. body habitus)
Subject has a history of hypercoagulation/clotting disorders or acute thrombosis
Subject has allergy to iodinated contrast media that cannot be adequately managed with medication
Subject is in acute renal failure
Subject has an active systemic infection
Subject is participating in another research study involving an investigational device, biologic, or drug that has not completed the primary endpoint at the time of randomization/enrollment
Subject has other comorbidities that - in the opinion of the investigator - preclude them from receiving study treatment and/or from completing the required study follow-up assessments
Subject presents with acute limb ischemia or acute thrombosis of the target limb
Failure to successfully treat clinically significant inflow lesions in the ipsilateral iliac, femoral, or popliteal arteries. Successful treatment is defined as obtaining ≤30% residual stenosis with no major procedural complications (e.g embolism)
Subject has experienced myocardial infarction, thrombolysis, or angina less than 30 days prior to the index procedure
Failure to successfully treat significant non-target infra-popliteal lesions. Successful treatment is defined as obtaining ≤30% residual stenosis with no major procedural complications (e.g. embolism)
Subject had a stroke within 3 months of index procedure
Target lesion is within a previously placed stent
Angiographic exclusion criteria
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note